Abstract. Purpose: The first aim of the study was to investigate the diagnostic potential of 11 C-acetate PET in the early detection of prostate cancer recurrence. A second aim was the evaluation of early and late PET in this context. Methods: The study population comprised 32 prostate cancer patients with early evidence of relapse after initial radiotherapy (group A) or radical surgery (group B). The median PSA of group A (n=17) patients was 6 ng/ml (range 2.6-30.2) while that of group B (n=15) was 0.4 ng/ ml (range 0.08-4.8). Pelvic-abdominal-thoracic PET was started 2 min after injection of 11 C-acetate and evaluated after fusion with CT.
Introduction
Conventional radiology of recurrent prostate cancer has a low sensitivity and specificity because of difficulties in differentiating between recurrent tumour and repair tissue after surgery and/or radiation therapy (RT). 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) also has a low sensitivity owing to the modest glucose consumption of these tumours and the proximity of the urinary tract, with high background activity [1, 2] .
Promising results in the detection of recurrent prostate cancer have been obtained with the newer PET tracers 11 Cacetate, 11 C-choline and 18 F-fluorocholine [3] [4] [5] [6] [7] . Radiolabelled acetate and choline are partially integrated as phosphatidylcholines into the cellular membranes of proliferating cells, another part being catabolised [8] . PET with these tracers could thus show biological functionality of radiologically suspicious lesions.
Recently, nanoparticle-enhanced magnetic resonance imaging (MRI) has emerged, yielding encouraging results [9, 10] . Endorectal MRI could provide the most interesting information concerning local disease [11, 12] , notably in distinguishing T2 and T3 stages [13] . However, the interpretation following radiotherapy remains challenging owing to the difficulty in differentiating between post-RT signal modifications and tumour relapse [14] . In the latter situation, a higher specificity has been described for MR spectroscopy [14] than for endorectal MRI.
Independent of the radiological evaluations, tumour relapse is, as would be expected, more frequent in high-risk prostate cancer patients. A consensus statement of the American Joint Committee on Cancer (AJCC) defined advanced T staging (T ≥pT2c), high tumour grades (sum of Gleason score ≥8) and high pre-surgical serum prostatespecific antigen (PSA) values (>20 ng/ml) as the three major risk parameters of prostate cancer [15] . Positive surgical margins, seminal vesicle invasion and capsular involvement represent further risk parameters [16] [17] [18] .
Several of the initial 11 C-acetate or 11 C-or 18 F-choline PET studies [3] [4] [5] [6] [7] were performed in patients with rather high PSA values, suggestive of advanced disease. A more significant contribution for patient management might be expected from PET performed at earlier stages of tumour recurrence. However, a first evaluation of 11 C-acetate PET showed a low sensitivity of only 7% in post-surgical patients with PSA values below 3.0 ng/ml [4] .
Definition of biochemical recurrence is clearly different after initial radical surgery or radiotherapy. Radical surgery eliminates all prostate tissue and PSA is expected to fall below the detection limit. Thus, recurrence in these patients is already suspected at the earliest rise in PSA [19] [20] [21] . It has been shown that even very low PSA values of 0.1-0.2 ng/ml following radical surgery represent a probability for further rise in PSA and tumour recurrence of 90% [22] . The risk would be 67% at PSA values ≤0.1 ng/ml according to this study [22] .
Regarding patients with first-line RT, definition of recurrence by reference to rising PSA remains a matter of debate. An ASTRO consensus statement of 1997 required the measurement of three consecutive increases in PSA [23] . More recently, a retrospective analysis of 4,800 patients [24] showed that other definitions of recurrence would be slightly more sensitive and specific than the ASTRO criterion. After RT, measurement of two consecutive PSA increases of at least 0.5 ng/ml each, or a PSA value ≥2 ng/ml above nadir, would provide sensitivities and specificities for recurrence of between 64% and 78% [24] . Considering these rather modest results for sensitivity and specificity, it is obvious that the definition of treatment failure following RT remains difficult. A strong suspicion of recurrence will generally be established at PSA values significantly higher than 2 ng/ml.
Salvage RT of post-surgical patients with recurrent cancer has been studied by different groups. It has been shown that a PSA value >2 ng/ml is a bad prognostic factor [25] . Accordingly, salvage RT should be performed as early as possible. As a challenge for PET, the most interesting patient population in the post-surgical situation would therefore present very low PSA values. Tumour size in these patients will be particularly small and PET partial volume effects will be frequently observed. As a consequence, the predictive value of the standardised uptake value (SUV) in these patients might be compromised. As mentioned, a first evaluation of 11 C-acetate PET in post-surgical patients with PSA values below 3 ng/ml showed a disappointingly low sensitivity [4] . A commentary questioned the methodology of this study, such as the absence of SUV measurement and the low number of histological confirmations [26] .
The first aim of the present study was to investigate the diagnostic potential of 11 C-acetate PET in the early detection of prostate cancer recurrence. Patients were studied at biochemical relapse after initial RT (group A) or radical surgery (group B). Based on the above-mentioned considerations, SUV max , though calculated for all areas of focal uptake, was not used in the PET interpretation of patients from group B.
A second aim was the evaluation of early and late PET. In fact, while several studies have suggested that tumour uptake of 11 C-acetate is very rapid [7, 27] , the retention time in tumours of individual patients has not been described. Late PET was performed with the intention of ascertaining whether individual tumours remained positive.
Materials and methods

Patient population
All patients gave their written informed consent to the study protocol, which had been approved by the ethical commission of the hospital and the Swiss authorities (Swissmedic and Federal Office of Public Health, Section of Radioprotection). The consecutive PET studies presented here were performed from December 2004 to July 2005.
Two groups were evaluated. Patients of group A (n=17) had been treated initially with RT. Table 1 summarises their clinical status and their biochemical status initially and at PET. Median tumour radiation dose was 74 Gy (range 64-78.4 Gy). Nine (53%) of the 17 patients presented one or more of the three high-risk factors as previously described [15] . The rise in PSA after nadir post RT was significant and confirmed at least once.
Patients of group B (n=15, numbered 18-32) were treated initially with radical surgery. Table 2 summarises their clinical status and their biochemical status initially and at PET. All 15 patients presented one or more of the three high-risk factors [15] . Many patients of this group presented further risk factors [16] [17] [18] , such as histologically positive surgical margins (n=11), invasion of seminal vesicles (n=4), capsular invasion (n=9) or perineural invasion (n=13).
11
C-acetate 11 C-acetate was prepared at the cyclotron unit of Geneva University Hospital from 11 C-carbon dioxide produced on an IBA 18/9 cyclotron, according to a modified [28] , previously published procedure [29] . In brief, 11 C-acetate was prepared based on a combination of the captive solvent radiolabelling "Grignard" reaction [30] conducted in the sterile catheter extension tube, followed by the convenient solid-phase extraction purification [29] on a series of ion-exchange cartridges. The requested radiochemical purity of the patient formulations, as determined by high-performance liquid chromatography, was ≥95%. Mean radiochemical purity of 11 Cacetate at injection was 98.2±1.6%.
PET, CT and fusion
The PET scanner used was the ECAT ART (Siemens/CTI, Knoxville, TN, USA). After bladder voiding, patients were placed in the scanning position and six-run transmission scanning (5 min/bed position) using 137 Cs single-photon point sources was recorded starting at the prostate bed. The laser-defined starting position was marked in ink on the patient's leg. Patients were then injected, applying standard precautions, with an activity of 520 MBq 11 Cacetate. This activity was selected in order to cover the long scanning time of a trunk scan as performed here. The emission scan was started 2 min after acetate injection, comparable with previous studies [7, 27] . The initial run of 10 min was centred on the prostate bed, followed by five runs of seven minutes each covering the rest of the pelvis, abdomen and thorax. A final run of 10 min, started at 47 min post injection, was again again on the prostate bed.
In a typical PET scan and for a patient injected with 520 MBq 11 C-acetate, the number of trues per bed position was about 12-18×10 6 counts on the first six runs and about 8×10 6 counts on the final prostate bed-centred run. The initial modest number of trues per time unit reflects the low sensitivity of the partial-ring tomograph and its low count rate performance for the relatively high activity injected since the peak noise equivalent count rate for a 20-cm-diameter cylinder is 27 kcps at a concentration of 15 kBq/ml [31] . It should be emphasised that the performance of the camera can be improved by operating the scanner with a decreased block integration time and reduced coincidence time window [32] . CT imaging was performed between 2 and 48 h after the PET scan on a Siemens Sensation 16 scanner. The starting position of the dedicated fusion CT, marked with two metallic needles, was identical to that of the PET scan (ink marks), as verified by the same physician. PET-CT image fusion in the first four patients used the standard contrast-enhanced thoracic-abdominal-pelvic CT. It showed the major difficulties in the alignment of PET and CT data acquired in different scanning positions and with different breathing. Subsequently, patients had a non-contrast-enhanced CT for image fusion acquired in the PET position (arms held along the body) and with flat breathing. The non-contrast-enhanced CT was finally modified to a low-dose CT [33] in the PET position and flat breathing using 120 kV, 60 mAs and a pitch of 1.5 and a 1-s rotation. Under the latter condition, the mean effective radiation dose for an adult patient was 3.5 mSv, as calculated using the IMPACT CT patient dosimetry calculator (http://www.impactscan.org/ctdosimetry.htm).
PET images were reconstructed using iterative attenuationweighted ordered subset expectation maximisation (OSEM). An attenuation correction matrix was calculated by segmenting the attenuation map, followed by forward projection at appropriate angles of the transmission image [34] . The generated attenuation correction map was used to reconstruct the emission data. The images were scatter corrected and reconstructed by using normalised attenuation-weighted, OSEM iterative reconstruction implemented with the ECAT 7.2 software. The default parameters used were OSEM iterative reconstruction with two iterations and eight subsets followed by a post-processing Gaussian filter (kernel full-width halfmaximal height, 6 mm). The voxel size was set to 3.4×3.4×3.4 mm 3 . Attenuation-corrected views were obtained in transaxial, coronal and sagittal planes.
One of the surgically treated patients (patient 26) had a hip prosthesis that led to a CT artefact projecting on the prostate bed. His PET/CT fusion scan was therefore analysed without and with attenuation correction. All other patients had their attenuationcorrected PET/CT fusion scan evaluated.
PET to CT image co-registration was performed using the commercial Hermes multi-modality fusion software (Nuclear Diagnostics AB, Stockholm, Sweden).
Standardised uptake values (SUV) were calculated [35] as follows: SUV=lesion activity per gram/(injected activity/patient body mass (g)). Mean and maximal SUV were calculated for ROIs of focal uptake and compared with adequate control regions to derive tumour to non-tumour (T/N) ratios.
A standard, contrast-enhanced CT was available for all patients. It was consulted for PET interpretation if suspicious foci of uptake in the abdomino-pelvic region suggested the presence of adenopathies or if other structures generated focal uptake, such as degenerative osseous disease, and the low-dose CT did not present the necessary resolution to allow their clear definition. a Indicates high-risk patient characteristics PET interpretation was performed by two experienced nuclear medicine physicians who gave their final consensus statement in the clinical report as tumour positive, equivocal or tumour negative.
Salvage RT and follow-up
Salvage RT in post-surgical patients was performed with 18 MV-Xrays using a Clinac 2100-C linear accelerator and an irradiation technique of four fields (anterior, posterior and two lateral). RT was delivered in five weekly fractions of 2 Gy/day to a total of 32 fractions (64 Gy) directed on the prostate bed. A boost dose of five fractions (10 Gy) was delivered to tumour recurrences, whenever such a recurrence was shown by endorectal MRI and/or 11 C-acetate PET.
Provided there was an adequate interval from initial RT and absence of distant disease in patients of group A, in these patients a second, salvage RT was proposed after hormonal therapy. Secondary salvage RT used 18-MV X-rays generated by the Clinac 2100-C linear accelerator and administered using the standard protocol of 5× weekly at 1.8 Gy/day up to 45 Gy (25 fractions). External beam RT was then completed with 18 Gy brachytherapy.
All included patients accepted the complementary evaluation with endorectal MRI and a diagnostic contrast-enhanced thoracoabdominal-pelvic CT. Bone scintigraphy was performed in eight patients of group A and in seven patients of group B.
Patients of group A had various further evaluations. Biopsies as the gold standard for local disease were indicated prior to salvage RT in the absence of evidence of systemic disease. Endorectal MRI was performed in 12 patients and completed with MR spectroscopy in nine [14] . Patients with disseminated disease as shown by radiology received hormonal therapy alone.
Patients who had undergone initial radical surgery were proposed salvage RT based on their situation of high-risk prostate cancer in the absence of evidence, with the exception of a single positive obturator lymph node in one patient, of dissemination both at initial surgery and at relapse. One patient of this group with a particularly aggressive tumour (Gleason 5+5) was initially given anti-hormonal treatment, followed by salvage RT.
Response to salvage RT was taken as a safe indication for local relapse. Thus, a reduction in the PSA value by ≥50% 6 weeks after completion of RT, compared with the initial value, served as surrogate proof for the presence of tumour. Biochemical response after salvage RT, whereby PSA values had decreased to less than 0.04 ng/ml (detection limit), indicated an optimal local response, providing the strongest evidence for the presence of localised disease alone.
Statistical analysis
For evaluation of the statistical correlation between early and late prostate PET, the inter-category variation kappa test was performed 
Results
All 11 C-acetate injections (518±18 MBq, radiochemical purity 98.2±1.6%) were well tolerated.
The principal characteristics of the 17 patients in group A, treated initially with RT, are summarised in Table 1 . Nine patients (53%) presented one or more high risk factors. The rise in PSA in these patients was significant, reaching a median value of 6 ng/ml at PET. The median delay between initial radiotherapy and PET was 61.7 months.
The characteristics of the 15 patients in group B are presented in Table 2 . All were at high risk, presenting one or more of the three major risk determinants according to the consensus statement ( Table 2) . Eleven patients had histologically positive surgical margins, highly suggestive of residual local disease. Twelve patients had a confirmed increase in PSA observed 7-52 months after surgery. The three other patients underwent the 11 C-acetate PET between 3 and 5 months post radical surgery based on a PSA that did not return to baseline but remained elevated at between 0.24 and 0.51 ng/ml. These elevated values were confirmed before salvage RT. The median delay between surgery and PET was 24.1 months, and a median PSA of 0.4 ng/ml was measured within 1 month of PET. PSA was below 0.8 ng/ml in 11 of 15 patients.
PET in patients treated initially with RT
In group A, focal uptake with an SUV max ≥2 were considered abnormal. Focal uptake <2 was considered equivocal. According to these criteria, 14 patients (82%) were positive (Figs. 1, 2) and two (12%) equivocal for local recurrence. Mean SUV max of positive and equivocal results was 2.9 and the mean T/N ratio was 2.4 (Table 3) .
With regard to lymph node disease, five patients showed focal 11 C-acetate uptake. In detail, three patients had lymph nodes with a SUV max higher than 2.0, another patient had one node that was clearly positive and one that was equivocal, and one patient had one equivocal result. In comparison with CT, three patients (patients 2, 3 and 9) had positive or equivocal 11 C-acetate PET for adenopathies as defined by CT with lymph node diameters ≥1 cm. Two patients had a positive or equivocal PET scan (patients 16 and 13, respectively) for lymph nodes smaller than 1 cm in diameter that were not considered suspicious on the basis of radiological criteria.
With regard to M staging, a biopsy-proven metastasis of the corpus cavernosum was highly positive on PET (SUV max 6.3). Contrast-enhanced CT, performed in all patients, and bone scintigraphy, performed in eight patients, were positive or suspicious for bone metastases in four patients. However, only two of the multiple vertebral metastases were rated positive by PET (in patient 15) while three suspicious lesions of the ribs and two lumbar vertebrae were negative on PET. One suspicious lesion of the skull was outside the PET scanning field.
At late pelvic PET, following the observation of decreasing SUV max of initially positive lesions, a positive cut-off level of 1.5 was used. Late PET of the prostate bed C-acetate PET of patient 8 performed 30 months post RT. PSA before RT combined with hormonal therapy was 21.8 ng/ml and it fell to 0.3 ng/ml after treatment. PSA later rose rapidly to 8.0 ng/ml at PET, with a short doubling time of 2 months. PET scan at seminal vesicle level (a) is shown, together with the corresponding fused imaging (b) and CT (c). Note the focal uptake on the right, with a SUV max of 2.0, and a smaller focus on the left. Endorectal MRI (not shown) completed with MR spectroscopy showed an extended lesion infiltrating bilaterally into the seminal vesicles was positive for local recurrence in 13 patients (77%) and equivocal in three (18%). The mean SUV max of positive/ equivocal results was 2.0±0.7 and the mean T/N ratio, 2.3±0.6. When analysing early and late PET for correlation of positive, equivocal and negative results of local recurrence, concordance (p<0.05) was observed but kappa was moderate, with a value of 0.49.
Endorectal MRI was performed in 12 patients and completed with MR spectroscopy in nine. It indicated the presence of local recurrence(s) in all evaluated patients.
Definitive confirmation by histology (the gold standard for the presence of local disease) was indicated in patients who presented evidence of exclusive local recurrence. Biopsies were obtained from six patients and were all positive (100%). In comparison to initial grading, the Gleason score remained identical in three patients and increased by 1 point in the other three.
With regard to biopsy-proven recurrences (n=6), PET was positive in five of these patients and equivocal in one.
PET in surgically treated patients
The prostate bed of patients of group B was assumed to be empty of any prostate tissue after initial radical surgery. Furthermore, the interval between surgery and PET was long, at 3 months or more. Any post-surgical inflammatory response was therefore expected to have disappeared. Furthermore, the very low PSA values in many of these patients indicated the presence of very small tumour recurrences/residues. This hypothesis was supported by endorectal MRI, which showed the prevalence of frequently single, small tumour lesions. For these reasons, the SUV max values, while determined, were not used in the interpretation of the PET scan, since partial volume effects would artificially diminish these values.
Reading of the attenuation-corrected PET/CT fusion scans revealed five positive (Figs. 3, 4) and four equivocal results for local recurrence (Table 4) . A single lymph node of the obturator region was interpreted as positive in patient 32, its SUV max being 2.6. No further metastasis was detected in this group. The mean SUV max of locally positive and equivocal results was 2.1 and 1.5, respectively, while the corresponding T/N ratios were 1.9 and 1.6.
Eleven patients of group B had a PSA value <0.8 ng/ml at PET. Four were positive and two equivocal for a local recurrence.
The late PET centred on the prostate bed showed five positive and three equivocal results. In comparison to the early PET, the late scan showed one additional equivocal result while one early equivocal result became positive on the late scan. When analysing the correlation of early and late PET for local recurrence according to positive, equivocal and negative results, a significant concordance (p<0.001) was observed; however, the kappa coefficient was moderate, with a value of 0.59. Mean SUV max of the late positive and equivocal results was 2.0 and 1.8, respectively, while the corresponding T/N ratios were 2.1 and 1.6 (Table 4) .
Endorectal MRI was performed in all 15 post-surgical patients (Figs. 3, 4 , Table 4 ). It was interpreted as locally positive in 11 and suspicious in two cases. In the two patients with negative endorectal MRI, 11 C-acetate PET was also negative in one patient and equivocal in the late C-acetate PET of patient 7 performed 62 months post RT. PSA before RT was 6.3 ng/ml and it later rose again to 4.5 ng/ml at PET, with a doubling time of 8 months. PET scan at the prostate level (a) is shown, together with the corresponding fused imaging (b) and CT (c). Note the focal uptake on the right, with a SUV max of 2.7, and a smaller focus on the left, correlated with positive endorectal MRI. Rectal activity was high in this patient scan in the other. Positive/equivocal results of endorectal MRI in these patients concerned mostly a single focal lesion. An analysis of the spatial correlation between PET and MRI was performed according to the location of the observed recurrence. For the nine patients with positive/ equivocal results on both examinations, a spatial correlation was observed in seven (78%).
With regard to the single positive lymph node observed by PET in patient 32, this node was negative by other radiological criteria: ferromagnetic nanoparticle-enhanced abdominal MRI was interpreted as negative owing to the small size of the node (0.7 cm, measured on CT), a frank hypo-signal and uptake of the contrast medium. Endorectal MRI showed only a non-specific obturator lymph node signal.
Overall, no further suspicion of metastases in group B patients was noted except the obturator lymph node in patient 32. Contrast-enhanced whole-body CT was negative in all patients. Complementary bone scintigraphy performed in seven patients confirmed the suspicion of Paget's disease in one patient but was negative for bone metastases. All patients were therefore amenable to salvage RT that also encompassed the suspicious obturator lymph node.
Fourteen patients were evaluated for PSA evolution after salvage RT. A significant reduction in PSA by ≥50% after salvage RT was observed in eight patients (57%). Reduction in PSA after radiotherapy directed to the prostate bed is, in our opinion, close to representing proof of local tumour recurrence or residue. Of the eight patients with positive response to RT, three had a positive PET while in two other patients PET was equivocal. PSA fell below the detection limit in three patients, suggesting eradication of recurrent local disease. Interestingly, the three patients with optimal PSA response after salvage RT presented a PSA at RT initiation of <0.4 ng/ml (range 0.19-0.33), underlining the need to evaluate these patients at the earliest indication of recurrent disease. Only one patient (no. 19) had a frankly increasing PSA value after 1 month of RT, which was stopped and replaced by hormonal therapy. Five patients had no significant evolution of PSA at 6 weeks post salvage RT. One of these patients had a PSA of 0.08 ng/ml, the clinical relevance of which remains unclear currently.
Discussion
This study was performed in two groups of patients. Results of 11 C-acetate PET in post-RT patients showed a high number of local recurrences. In all six patients in whom biopsies were obtained, histology confirmed the local recurrences. The PET results in this group of patients presenting moderate PSA values are thus in agreement with previous reports.
The second group of patients, who had initial radical surgery, was studied at very low PSA values with a median of only 0.4 ng/ml. Here, 11 C-acetate PET was positive or a Mean±1 standard deviation and median SUV max and T/N ratios are given for positive and equivocal results combined ND not done equivocal for local recurrence in 9 of 15 patients. Even in the subgroup of 11 patients with PSA values <0.8 ng/ml, evidence for local recurrence was observed in a similar percentage. This result contrasts with the finding of a previous study, where a sensitivity of only 7% was reported for 11 C-acetate PET in patients presenting PSA values below 3.0 ng/ml [4] .
Tumour-positive biopsies in group A and response to RT in group B (as reflected by reduction in the PSA value) represent the strongest evidence for local disease in these patients. Of the patients meeting these criteria, five out of six in group A and three out of eight in group B were positive by PET. One further patient of group A and two patients in group B showed equivocal PET scans. The suboptimal percentage of PET-positive patients in group B might be related to the limited acquisition potential of the available PET scanner, as discussed below. The equivocal PET scans also might be a direct consequence of this fact.
Several factors might have contributed to the better results observed here in patients with low PSA values compared with the aforementioned report [4] . Firstly, the patient population studied here presented mainly stage 3 disease and positive surgical margins, highly suggestive of local recurrent or residual disease. In comparison, patients in the previous study presented mostly stage 2 prostate cancer, where rising PSA was possibly more frequently related to distant recurrence [26] . Secondly, we used image fusion of PET with CT. We feel that it is very difficult to evaluate small-volume areas of focal uptake in the prostate bed region given that rectal accumulation of 11 C-acetate can be quite high. Thirdly, PET interpretation was specifically tuned in order to deal with the expected small-volume recurrences and consequently partial volume effects in the post-surgical patients. This appeared compatible with the expected absence of residual prostate tissue and absence of any post-surgical inflammatory response.
In the follow-up of the post-surgical patients, histological confirmation of local recurrence was not performed, mainly for two reasons: first, the indication for salvage RT was supported sufficiently by the available data; second, the risk of a negative biopsy result was high in the presence of very limited disease. However, in these patients PSA decrease after salvage RT was taken as a safe indication of local tumour response. This interpretation is supported by the fact that after radical surgery, PSA values as low as 0.1 ng/ml most reliably reflect prostate cancer recurrence and/or residual disease [22] . In this respect, the single patient evaluated and re-treated at a PSA below 0.1 ng/ml (patient 28) should be interpreted with caution, since the 3-year survival rate without further increase in PSA in such patients may be as high as 33% [22] . 11 C-acetate PET of patient 23, performed 24 months post surgery. The pre-surgical PSA value of 13.2 ng/ml fell to 0.06 ng/ml before rising again to 0.26 ng/ml at PET. Prostate bed-centred PET scan (a) is shown, together with corresponding fused PET-CT (b) and endorectal MRI (c). Note the small area of focal uptake with a SUV max of 2.6. The focal PET uptake correlated with an endorectal MRI finding suspicious for a recurrence close to the urethral anastomosis. Salvage RT was rapidly initiated within 1 month of 11 C-acetate PET and resulted in a decrease in PSA to 0.06 ng/ml 6 weeks after RT termination
The significance of stable (four patients) or rising PSA (one patient) after salvage RT in the remaining postsurgical patients remains unclear currently. Presence of minor distant disease cannot be excluded. However, since PSA was measured only 6 weeks after RT, the PSA response could not be evaluated with certainty.
Given the high number of group A patients who were positive for local tumour recurrence on PET (many of these results being confirmed by histology), one might argue that in such patients 11 C-acetate PET could be performed earlier in the course of suspicious PSA measurements. On the other hand, it needs to be borne in mind that, particularly in younger patients, normal prostate tissue takes up 11 Cacetate in significant amounts [37] . However, it is not known to what degree normal prostate tissue of older patients in the post-RT situation accumulates 11 C-acetate, in particular after a long delay post RT. Our PET results clearly showed the presence of focal uptake while the background activity of normal prostate tissue was below SUV max 2, as shown by the T/N ratios.
PET was positive or equivocal for metastases in six patients of group A. These observations concerned mostly lymph node metastases, several of which were confirmed by CT. Another obturator lymph node was positive on PET in group B. Overall, three lymph nodes less than 1 cm in diameter were positive or equivocal on PET despite being unsuspicious by radiological criteria. However, it has not yet been possible to confirm these results, the follow-up being too short to date.
Despite the positive observations concerning lymph node disease, the sensitivity of PET for detection of distant disease appeared limited, notably for osseous metastases. This limited ability to detect distant metastases might have been partially related to the significant tracer uptake in the pancreas, intestinal tract and bone marrow in some patients. Focal uptake was also observed in degenerative bone and joint disease. Furthermore, the limited resolution of the available PET and the need to fuse PET with CT from a different machine might have contributed to a sub-optimal detection rate of metastases.
With regard to optimisation of the PET scanning time, tumour recurrences remained positive or equivocal in the large majority of patients at the late scanning time, two physical half-lives after the injection of 11 C-acetate. However, this study was not designed to identify the optimal timing for scanning. Dynamic scanning has been proposed previously [26] . Recently, in another study, 18 Ffluorocholine PET was investigated in the staging of primary prostate cancer. Results showed that late PET, performed 1 h after injection, allowed better differentiation The focal PET uptake correlated with the positive endorectal MRI for a small recurrence at the upper side of the penile bulb. Salvage RT was initiated within 40 days of 11 C-acetate PET and resulted in a decrease in PSA to 0.10 ng/ml 6 weeks after RT termination between benign and malignant prostate tumours when compared with early imaging [38] .
Two other recent studies addressed the value of integrated 18 F-fluorocholine PET/CT in patients with biochemical relapse when PSA values are less than 5 ng/ ml [39, 40] . Both studies showed the feasibility of fluorocholine PET at these PSA values, with a high number of positive findings. In comparison, in the group of postsurgical patients evaluated here, PSA was <0.8 ng/ml in 11 patients. Despite the very low PSA values, 11 C-acetate was positive or equivocal in the majority of these patients. Further studies are therefore warranted to establish the value of 11 C-acetate based on integrated PET/CT instrumentation and to compare these results with those obtained using 18 F-fluorocholine.
Conclusion
The results of this study show that 11 C-acetate PET may have significant potential for the detection of recurrent prostate cancer, most notably in the very early work-up of post-surgical patients. While in group A the number of locally positive PET studies was very high, suggesting that the examination was performed too late, in group B the number of positive patients was slightly lower, suggesting a limited sensitivity that might be improved in future evaluations. Some limitations were observed in this study that may have been related in part to the available PET scanner. While performance of the machine was tuned to a maximum, its acquisition potential remained limited by saturation, and in addition the resolution might have been lower than on modern PET/CT equipment. Further improvement might be obtained by PET/CT co-registration and by optimisation of scanning time, as indicated by the results shown here in the late pelvic scan. This study therefore shows, in contrast to a previous one, that 11 Cacetate PET may be of interest particularly in patients presenting very low PSA values following initial radical surgery, and possibly also earlier when there is a suspicious increase in PSA post RT. These situations might merit further evaluation of 11 C-acetate PET using more advanced PET/CT instrumentation. a PSA evolution after RT is shown: a decrease or increase by ≥50% in PSA 6 weeks post therapy compared with the initial value is indicated by ↓ and ↑, respectively. A PSA decrease to below the detection limit (0.04 ng/ml) after salvage RT is indicated by ↓↓. PSA variations of <50 % are denoted by ↔ b Salvage RT was interrupted because of a significant increase in PSA after 1 month therapy c Patient 29 presented a highly aggressive tumour (Gleason 5+5). He was re-treated with anti-hormonal therapy followed by RT and was therefore not evaluated for PSA evolution d Mean, 1 SD and median results are each given as two numbers for lesions interpreted as frankly positive or equivocal, respectively
